Table 1 Clinical findings of systemic sclerosis (SSc) cohort (n. 115 patients).
Clinical data | SSc patients |
|---|---|
Age at disease onset (years), mean ± SD | 56.58 ± 13.18 |
The hospitalization time (days), mean ± SD | 13.61 ± 5.67 |
The course of the disease (years), mean ± SD | 7.42 ± 8.25 |
Sex-male, n (%) | 19 (16.52%) |
Sex-female, n (%) | 96 (83.48%) |
Anti-nuclear antibodies, n (%) | 104(90.43%) |
Anti-centromere antibodies, n (%) | 29(25.22%) |
Anti-Scl-70 antibodies, n (%) | 37(32.17%) |
Anti-U1-SnRNP antibodies, n (%) | 22(20.37%) |
No of organs affected, n (%) | 14(12.17%) |
Organ involvement, n (%) | 101(87.83%) |
Cardiovascular diseases, n (%) | 19(16.52%) |
Interstitial lung disease, n (%) | 76 (66.09%) |
Pulmonary arterial hypertension, n (%) | 32(27.83%) |
Gastrointestinal involvement, n (%) | 54(46.96%) |
Renal involvement, n (%) | 10(8.70%) |
Joint/tendon involvement, n (%) | 38(33.04%) |
Raynaud’s phenomenon, n (%) | 100(86.96%) |
Diffuse cutaneous SSc (dcSSc), n (%) | 89(77.39%) |
Limited cutaneous SSc (lcSSc), n (%) | 26(22.61% |
Active patients with disease activity index > 3 EScSG-AI, n. (%) | 54(46.96%) |
